Swiss drug development company Relief Therapeutics (SWX:RLF) and its US partner, pharmaceutical company, NeuroRx, have struck deals with Bachem and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, Reuters news agency reported on Wednesday.
Reportedly, aviptadil is in clinical trials against COVID-19.
According to the companies, the deal with Swiss technology company Bachem, to supply peptides, and US generics maker Nephron, to manufacture aviptadil, also being called RLF-100 by the companies, is aimed at having supplies sufficient to treat one million patients, should the drug prove effective in the studies.
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic